Fig. 2: Relationship between baseline tumor fraction of circulating tumor DNA and clinical prognosis. | British Journal of Cancer

Fig. 2: Relationship between baseline tumor fraction of circulating tumor DNA and clinical prognosis.

From: Prognostic significance of circulating tumor DNA alterations in advanced renal cell carcinoma from SCRUM-Japan MONSTAR-SCREEN: a nationwide genomic profiling project

Fig. 2: Relationship between baseline tumor fraction of circulating tumor DNA and clinical prognosis.

a Progression-free survival (PFS) and overall survival (OS) after initiating treatments according to tumor fraction at baseline in the overall cohort. b PFS and OS after initiating the combination therapy of first-line immune checkpoint inhibitors according to tumor fraction at baseline. c OS depending on the specific mutational status of circulating tumor DNA at baseline. Differences between the two groups were assessed using the log-rank test.

Back to article page